glp-1 blindness NAION and GLP1s: Rare Cause of Linked to Medication | Michael Weintraub, MD posted on the topic Glp1 blindness risk update :
Description
A: According to clinical trial data and FDA review: Clinical trials have studied GLP-1 medications for chronic weight management for up to 2-3 years, demonstrating acceptable safety profiles for most individuals during this timeframe

For traders, understanding both the upside drivers and downside risks is critical when approaching LLY in 2026

A recent study suggests that the use of GLP-1 receptor agonists was associated with better outcomes compared with the use of DPP-4 inhibitors among patients with type 2 diabetes and advanced-stage chronic kidney disease
Purpose-built for physicians GLP-1 does not slow Parkinsons disease progression in phase 3 study Key takeaways: Previous studies suggest GLP-1 receptor agonists may benefit those with Parkinsons disease

This privacy factor isn't trivial
To get the best results from Semaglutide GLP-1, it is important to follow the dosing instructions provided by your healthcare provider